Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04702243 · ClinicalTrials.gov registry record
Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 436
- Enrollment target
NCT04702243 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 436 participants.
The verdict
NCT04702243 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 436 participants
- Enrollment target
Study Summary
The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).
Interventions
- DIAGNOSTIC_TEST Genetic Testing for PCD or PID
- OTHER Unaffected Family Member Genetic Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 436 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2025-08-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04702243
The ClinicalTrials.gov registry entry for NCT04702243 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 436 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Genetic Testing for PCD or PID is the first listed.
NCT04702243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04702243 about?
NCT04702243 is a clinical study titled "Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults". The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).
What is the current status of trial NCT04702243?
This trial is currently completed. The enrollment target is 436 participants. The study started on 2020-12-01. Estimated completion is 2025-08-06.
What interventions are being tested in trial NCT04702243?
The interventions under investigation include: Genetic Testing for PCD or PID (DIAGNOSTIC_TEST), Unaffected Family Member Genetic Testing (OTHER).
Who is sponsoring clinical trial NCT04702243?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.